HealthcareCerebral is under federal investigation

Cerebral is under federal investigation


Cerebral, the digital mental health ‘unicorn’, said on Saturday it was under investigation by the federal government for “possible violations of the Controlled Substances Act.”  

The company said it received a grand jury subpoena from the U.S. Attorney’s Office for the Eastern District of New York on May 4.

In a statement to Digital Health Business & Technology, Cerebral said at this time no regulatory, or law enforcement authority has accused Cerebral of violating any law. Cerebral said it will cooperate with the investigation.

Business Insider reported on May 4 that the U.S. Drug Enforcement Agency was investigating Cerebral and speaking with former employees over the way it has prescribed controlled substances for attention deficit hyperactivity disorder (ADHD). At the time, Cerebral said, “We don’t speak for the DEA but are unaware of anything other than normal course interactions in the ordinary course of our business.”

The company’s ADHD medication policy sparked a lawsuit two weeks ago. In the complaint, Matt Truebe, former Cerebral vice president of product and engineering, alleges the company aimed to increase customer retention by prescribing ADHD stimulants to 100% of its patients. The lawsuit also alleges that Cerebral had 2,000 duplicate shipping addresses, which suggested patients were setting up multiple accounts to obtain additional medication from prescribers.

Cerebral has denied the allegations.

Download Modern Healthcare’s app to stay informed when industry news breaks.

Previously, The Wall Street Journal reported national pharmacy chains were probing the prescription practices at Cerebral and another company, Done Health. The story alleged CVS Health, Walmart and Walgreens reportedly blocked and delayed some Cerebral and Done Health prescriptions due to Adderall over-prescribing concerns. Online pharmacy, TruePill confirmed to the Journal that it paused Adderall and other controlled substances prescription fulfillment.

Cerebral and Done Health separately disputed the report and said delays in prescription happen for administrative reasons involving insurance companies and availability of medicine. During the public health emergency, the Drug Enforcement Agency waived prior in-person evaluation requirements for controlled substance prescriptions via telehealth.

Cerebral received a $300 million funding round in December and is valued at nearly $5 billion.



Original Source Link

Latest News

Nvidia just crushed earnings again. Top analyst says it’s another ‘drop the mic’ moment that confirms the AI revolution

Will all the AI hype lead to lasting earnings results that live up to Wall Streets’ lofty expectations?...

Why Beyoncé’s ‘Texas Hold ’Em’ Has Taken Over TikTok

In her delightfully cheeky Verizon Super Bowl commercial, Beyoncé swore to do one thing: Break the internet. As...

Wellstar Eyes Expansion At Paulding Medical Center In Hiram, Georgia

Wellstar Health System (Marietta, Ga.) is planning a $304 million patient tower at its Paulding Medical Center in...

Jim Jordan Goes Dumpster Diving To Try To Save Biden Impeachment

Biden impeachment looks dead, but that didn’t stop Rep. Jim Jordan from trying to save the effort to...

A new book explores the transformative power of bird-watching

Aaron Tremper is the editorial assistant for Science News Explores. He has a B.A. in English (with minors...

Must Read

- Advertisement -

You might also likeRELATED
Recommended to you